[Asia Economy Reporter Jang Hyowon] Jinwon Life Sciences announced on the 27th that it has signed a plasmid DNA pharmaceutical supply contract worth 3.6 million USD (approximately 4 billion KRW) with a multinational pharmaceutical company. The contracting party has not been disclosed in accordance with the contract.
Jinwon Life Sciences' subsidiary VGXI operates a contract development and manufacturing organization (CDMO) facility compliant with current Good Manufacturing Practice (cGMP) standards, producing and supplying high-quality plasmid DNA pharmaceuticals. Recently, VGXI received the CMO Excellence Award at the 2020 Vaccine Industry Excellence (ViE) Awards hosted by the World Vaccine Congress.
Park Younggeun, CEO of Jinwon Life Sciences, stated, “Following the commercialization of gene therapies, clinical development is actively progressing, and there is a rapidly increasing demand for high-quality plasmid DNA pharmaceuticals as raw materials for gene therapies.”
He added, “The construction of VGXI’s new production facility, which is being promoted to meet the growing demand, is proceeding as planned, and we are currently in discussions with several companies regarding supply.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
